natural_product

This is an old revision of the document!


Natural product

In a review article (mechanistic overview on mitochondrial regulation by natural products) Qin et al. from the Qingdao Medical College & Qingdao University, Pharmaceutical University, Nanjing published in the Neural Regeneration Research journal to summarize how natural products modulate mitochondrial dysfunction (biogenesis, dynamics, transport, mitophagy, apoptosis, oxidative stress) for stroke treatment, and identify barriers to clinical translation. Natural products act via multi-target mechanisms on mitochondrial processes to exert neuroprotection in both ischemic and hemorrhagic stroke models, but clinical translation is impeded by product complexity, lack of standardization, insufficient multicenter data, and unclear long-term safety. Future directions include advanced technologies (single-cell sequencing, organoid models) and multicenter trials 1).

*✅ Strengths*

  • Comprehensive mechanistic mapping: the article clearly organizes effects into six mitochondrial regulatory domains and links specific natural compounds (e.g., Cordyceps, ginsenosides, Gypenoside XVII, Ginkgolide K, Scutellarin, Chrysophanol) to distinct pathways of protection.
  • Provides molecular insights: for instance, Cordyceps activates PGC‑1α/NRF‑1 to enhance biogenesis; Gypenoside XVII activates PINK1/Parkin mitophagy to protect the BBB.
  • Identifies translational challenges—standardization issues, safety gaps, and absent systemic trials are analyzed realistically, demonstrating awareness of clinical hurdles.

*❌ Weaknesses*

  • Lacks summary of methodological rigor: no discussion of dosage, sample sizes, or statistical quality of cited in‑vivo/in‑vitro studies.
  • Minimal critical evaluation: the review treats molecular mechanisms as established without weighing conflicting data or study bias.
  • Omits pharmacokinetic/toxicology details: crucial for natural products, but not addressed.

Score: 7/10 – Strong mechanistic organization and translational awareness, but limited methodological critique and insufficient attention to pharmacokinetics and evidence quality.

Natural compounds show multi-faceted neuroprotection via mitochondrial modulation in animal/stem cell stroke models. However, they are not yet ready for clinical use due to regulatory, safety, and reproducibility gaps. Neurosurgeons should await human data before considering these agents.

A well-structured mechanistic review that identifies promising mitochondrial-targeting natural products, but lacks rigorous evaluation of experimental quality and clinical feasibility—future translational efforts are needed.

blogcategory Neurosurgery Reviews tags mitochondrial dysfunction, natural products, stroke, PGC‑1α, mitophagy, translational medicine

Title: Modulation of mitochondrial dysfunction: Mechanisms and strategies for the use of natural products to treat stroke Full citation: Qin N, Liu R, Deng R, Shi L, Wang L, Zhu T, et al. Modulation of mitochondrial dysfunction: Mechanisms and strategies for the use of natural products to treat stroke. *Neural Regen Res*. 2025 Jul 5. doi:10.4103/NRR.NRR‑D‑25‑00016.


1)
Qin N, Liu R, Deng R, Shi L, Wang L, Zhu T. Modulation of mitochondrial dysfunction: Mechanisms and strategies for the use of natural products to treat stroke. Neural Regen Res. 2025 Jul 5. doi: 10.4103/NRR.NRR-D-25-00016. Epub ahead of print. PMID: 40618255.
  • natural_product.1751831734.txt.gz
  • Last modified: 2025/07/06 19:55
  • by administrador